MUTUAL TERMINATION OF COLLABORATION AND LICENSE AGREEMENTMutual Termination Agreement • November 13th, 2024 • Seres Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This MUTUAL TERMINATION OF COLLABORATION AND LICENSE AGREEMENT (the “ROW License Agreement Termination Agreement”) is effective on September 30, 2024 (“ROW License Agreement Termination Effective Date”), and is made by and between Seres Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, having an office located at 101 Cambridge Park Drive, Cambridge, MA 02140, USA (“Seres”) and Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland, having an office located at Avenue Nestlé 55, 1800 Vevey, Switzerland (“NHSc”). Seres and NHSc are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
MUTUAL TERMINATION OF LICENSE AGREEMENTMutual Termination of License Agreement • November 13th, 2024 • Seres Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This MUTUAL TERMINATION OF LICENSE AGREEMENT (the “US License Agreement Termination Agreement”) is effective on September 30, 2024 (“US License Agreement Termination Effective Date”), and is made by and between Seres Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, having an office located at 101 Cambridge Park Drive, Cambridge, MA 02140, USA (“Seres”) and Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland, having an office located at Avenue Nestlé 55, 1800 Vevey, Switzerland (“NHSc”). Seres and NHSc are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
